BGT007H Cells for the Treatment of Recurrent/Refractory Gastrointestinal Tumors

Inclusion Criteria: * 1\. Resources sign written informed consent; * 2, age ≥18, male and female can; * 3\. Expected survival ≥3 months; * 4\. The Eastern Cancer Collaboration (ECOG) physical status score was 0-1; * 5\. Biopsy specimen or pathological wax section test (within 3 years before accepting the signed informed consent) : positive target test; * 6\. According to RECISTv1.1 solid tumor evaluation criteria, there is at least one measurable lesion; * 7\. Patients with advanced gastrointestinal tumors (esophageal cancer, gastric cancer, pancreatic cancer or colorectal cancer, etc.) who have been diagnosed by histology/cytology as having failed the standard of second-line or above treatment or are not suitable for/refuse to accept the standard treatment or cannot tolerate the standard treatment; The definition of intolerance: according to CTCAE V5.0, the occurrence of ≥Ⅳ hematological toxicity or ≥Ⅲ non-hematological toxicity or ≥Ⅱ damage to the heart, liver, kidney and other important organs during treatment; Treatment failure is defined as disease progression (PD) during treatment or recurrence after the end of treatment (including postoperative recurrence); * 8, can establish monopexy or venous blood collection venous access, and there are no other contraindications for blood cell separation; * 9, with adequate organ and bone marrow function; * 10\. During the study period and for 6 months after the end of dosing, fertile subjects (both male and female) must use effective medical contraception. For female subjects of reproductive age, a pregnancy test should be performed within 72 hours before the first dose, and the result is negative. Exclusion Criteria: * 1\. Active central nervous system metastasis (except stable after treatment); * 2, HIV positive, HBsAg positive simultaneously detected HBV DNA copy number positive (quantitative detection ≥1000cps/ml), HCV antibody positive and HCV RNA positive; * 3, mental or mental illness can not cooperate with treatment and efficacy evaluation; * 4\. Subjects with severe autoimmune diseases and long-term use of immunosuppressants; * 5\. Active or uncontrollable infection requiring systemic treatment within 14 days prior to enrollment; * 6\. Any unstable systemic disease (including but not limited to: Active infections (except local infections); Unstable angina pectoris Cerebral ischemia or cerebrovascular accident (within 6 months prior to screening) Myocardial infarction (within 6 months prior to screening) Congestive heart failure (New York Heart Association \[NYHA\] classification ≥Ⅲ; Severe arrhythmias requiring medical treatment; Have heart disease that requires treatment or uncontrolled hypertension after treatment (blood pressure \> 160mmHg/100mmHg); * 7, combined with lung, brain, kidney and other important organ dysfunction; * 8\. The subject has undergone major surgery or severe trauma within 4 weeks prior to receiving cell therapy, or is expected to undergo major surgery during the study period; * 9\. Received any systemic chemotherapy, immunotherapy or small molecule targeted therapy within 1-2 weeks or 5 half-lives (whichever is shorter) before anapheresis; * 10\. The subject currently has or has had other malignant tumors that cannot be cured within 3 years, except cervical cancer or basal cell carcinoma of the skin, and other malignant tumors with a disease-free survival of more than 5 years; * 11, received chimeric antigen receptor modified T cells (including CAR-T, CTT-T) treatment within half a year; * 12\. Combined graft-versus-host disease (GVHD) * 13\. Subjects who were receiving systemic steroid therapy prior to screening and who were determined by the investigator to require long-term use of systemic steroid therapy during treatment (except for inhalation or topical use); And subjects treated with systemic steroids within 72 hours prior to cell transfusion (except for inhalation or topical use); * 14\. Severe allergy or history of allergy; * 15\. Subjects requiring anticoagulation therapy; * 16, pregnant or breastfeeding women, or six months within the pregnancy plan (unisex; * 17\. Researchers believe that there are other reasons for not being included in the treatment.